Clinical Trial Update: Activity and Safety of Oral Administration of SSR150106XB for the Reduction of Inflammation in Patients With Active Rheumatoid Arthritis [Phase 2]

View source ↗

Summary

Phase 2 trial update reporting activity and safety of oral SSR150106XB for reducing inflammation in active rheumatoid arthritis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• SSR150106XB

Snippet

Sponsor: Sanofi | Conditions: Rheumatoid Arthritis | Phase 2 | Status: COMPLETED